Bengaluru’s Eyestem has secured CDSCO approval to commence human trials for Eyecyte RPE, targeting dry age-related macular degeneration (AMD). Founder Jogin Desai plans Phase 1/2a trials in 2-3 months, aiming to recruit volunteers within 6-8 weeks. The therapy aims to replace damaged retinal cells, potentially preserving/improving sight. With over 170 million affected globally, including 40 million in India, Eyecyte RPE offers hope for those with vision loss. Chief Medical Officer Rajani Battu highlights affordability and potential regulatory bypass due to India’s unmet need. Future plans include treatments for retinitis pigmentosa and idiopathic pulmonary fibrosis.